Market Cap (In CNY)
37.85 Billion
Revenue (In CNY)
2.12 Billion
Net Income (In CNY)
283.53 Million
Avg. Volume
3.05 Million
- Currency
- CNY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 12.08-34.0
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- KYG9808A1058
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Dr. Jincai Li Ph.D.
- Employee Count
- -
- Website
- https://wuxixdc.com
- Ipo Date
- 2012-06-18
- Details
- WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
More Stocks
-
GRE
-
KAJARIRK I C Metaliks Limited
KAJARIR
-
PSGFF
-
DMIFFDiamcor Mining Inc.
DMIFF
-
ADHADvTECH Limited
ADH
-
RGBP
-
SLI
-
TALBROSENGTalbros Engineering Limited
TALBROSENG